Precigen

Precigen is a pharmaceutical company that develops gene and cellular therapies for the treatment of immuno-oncology and autoimmune disorders. Read more

Helen Sabzevari's photo - President & CEO of Precigen

President & CEO

Helen Sabzevari

CEO Approval Rating

89/100

Founded:

1998

Status:

PublicIndependent CompanyNASDAQPGEN

PRECIGEN TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

Kite Pharma is one of Precigen's top competitors. Kite Pharma was founded in 2009, and its headquarters is in Santa Monica, California. Like Precigen, Kite Pharma also works within the Pharmaceuticals sector. Kite Pharma has 1,118 more employees than Precigen.

Incyte is Precigen's #2 rival. Incyte was founded in 1991 in Wilmington, Delaware. Incyte operates in the Pharmaceuticals industry. Incyte generates $2.6B more revenue than Precigen.

Poseida Therapeutics is a top competitor of Precigen. Poseida Therapeutics is a Public company that was founded in San Diego, California in 2014. Poseida Therapeutics competes in the Biotechnology field. Poseida Therapeutics has 676 fewer employees vs. Precigen.

Weigh-in!

Help the Owler community know more

Competitor - 1/1

Is Bellicum a competitor of Precigen?

Precigen Quarterly and Annual Revenue

Trailing 12-Months Trend (TTM)

Annual Revenue

$97.9M

Precigen's revenue is the ranked 5th among it's top 10 competitors. The top 10 competitors average 8.1B. Over the last four quarters, Precigen's revenue has decreased by 17.9%. Specifically, in Q1 2021's revenue was $24.5M; in Q4 2020, it was $49.8M; in Q3 2020, it was $23.6M; in Q1 2020, Precigen's revenue was $29.8M.

Precigen Acquisitions

COMPANY ACQUIRED
ACQUISITION DATE
AMOUNT
DESCRIPTION
Genvec Inc

Jan 2017

Source »
undisclosed
GenVec is a biopharmaceutical company that develops and builds a pipeline of therapeutics and vaccines for gene-based diseases.
EnviroFlight, LLC

Feb 2016

Source »
undisclosed
EnviroFlight is a food supply company that develops insect-based nutritional products for animals and plants.
Oxitec, Ltd.

Aug 2015

Source »
undisclosed
Oxitec is a UK-based biotechnology company that develops genetically modified insects to control pests that spread disease and damage crops.
ActoGeniX

Feb 2015

Source »
$60M
ActoGeniX is a biopharmaceutical company that focuses on developing and commercializing biological drugs.
Trans Ova Genetics LC

Jul 2014

Source »
$120M
Trans Ova Genetics provides reproductive technologies and animal husbandry service for cattle’s.

These are all the companies that Precigen has acquired. Precigen has acquired 5 companies and its latest acquisition was Genvec Inc in Jan 2017. GenVec is a biopharmaceutical company that develops and builds a pipeline of therapeutics and vaccines for gene-based diseases.

Precigen Funding History

Since Precigen was founded in 1998, it has participated in 20 rounds of funding. In total Precigen has raised $1.0B. Precigen's last funding round was on Dec 2020 for a total of $13.0M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Post-IPO Equity
Dec 2020
$13M
-
Post-IPO Equity
Jan 2020
$35M
-
Post-IPO Equity
Feb 2016
$4.3M
-
Post-IPO Equity
Sep 2015
$21.6M
-
Secondary Offering
Aug 2015
$200M

Since Precigen was founded in 1998, it has participated in 20 rounds of funding. In total Precigen has raised $1.0B. Precigen's last funding round was on Dec 2020 for a total of $13.0M

Precigen Investments

COMPANY

DESCRIPTION

AMOUNT

INVESTMENT DATE

ROUND

EXIT DATE

Oragenics is a biopharmaceutical company that develops and markets novel antibiotic vaccines for the treatment of infectious diseases.
$9.9M
Sep 29, 2013
Private Placement
-

These are all the companies that Precigen has invested in. Precigen has invested 5 companies and its latest investment was Genvec Inc in Jan 2017. GenVec is a biopharmaceutical company that develops and builds a pipeline of therapeutics and vaccines for gene-based diseases.

Precigen News

June 9, 2021Benzinga

Return On Capital Employed Insights

Precigen (NASDAQ:PGEN) reported Q1 sales of $24.51 million. Earnings fell to a loss of $17.69 million... See more »
May 28, 2021MarketScreener

Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers (Form 8-K)

(marketscreener.com) Departure of Directors or Principal Officers; Election of Directors; Appointment... See more »
May 12, 2021MarketScreener

Initiated Phase 1 clinical trial of PRGN-2012 AdenoVerse immunotherapy in patients with recurrent respiratory papillomatosis (RRP) (Form 8-K)

(marketscreener.com) - Initiated Phase 1 clinical trial of PRGN-2012 AdenoVerse immunotherapy in pati... See more »
May 11, 2021Medical Buyer

Precigen reports first quarter 2021 financial results

Precigen, Inc. a biopharmaceutical company specializing in the development of innovative gene and cel... See more »
May 10, 2021Zacks

Precigen, Inc. (PGEN) Reports Q1 Loss, Tops Revenue Estimates

Precigen, Inc. (PGEN) delivered earnings and revenue surprises of 31.25% and 23.51%, respectively, fo... See more »
April 28, 2021Zacks

Know the Trend Ahead of Q1 Release

Precigen, Inc. (PGEN) doesn't possess the right combination of the two key ingredients for a likely e... See more »
March 30, 2021MarketScreener

Announces Departure of Chief Financial Officer

(marketscreener.com) GERMANTOWN, Md., March 30, 2021 /PRNewswire/ -- Precigen, Inc., a biopharmaceuti... See more »

Precigen Press Releases

November 27, 2020NewsFile

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Precigen, Inc. (PGEN) Investors of December 4th Application Deadline, Encourages Investors with Losses to Contact Its Attorneys

San Francisco, California--(Newsfile Corp. - November 27, 2020) - Hagens Berman urges Precigen, Inc. ... See more »
November 16, 2020PR Newswire

Precigen Announces Dosing of First Patients with UltraCAR-T Cells Manufactured Using Proprietary UltraPorator System in Ongoing PRGN-3005 and PRGN-3006 Phase 1 Clinical Trials

GERMANTOWN, Md., Nov. 16, 2020 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical com... See more »
November 3, 2020GlobalNewswire

Moore Kuehn, PLLC Encourages Investors of CLSN, PGEN or TCMD to Contact Law Firm

NEW YORK, Nov. 03, 2020 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities law firm located on Wall ... See more »
November 2, 2020PR Newswire

Will host Pipeline and Data Update Call in Early December

GERMANTOWN, Md., Nov. 2, 2020 /PRNewswire/ -- Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical comp... See more »
August 10, 2020PR Newswire

Precigen ActoBio Announces Positive Topline Results from Phase 1b Study of AG019 ActoBiotics , A Novel Therapy Designed to Address the Underlying Cause of Type 1 Diabetes

GERMANTOWN, Md., Aug. 10, 2020 /PRNewswire/ -- Precigen ActoBio, an innovative clinical-stage biotech... See more »
August 6, 2020PR Newswire

Precigen Triple-Gene Provides Six-month Follow-up Data from Phase I Study of INXN-4001, a Multigenic Investigational Therapeutic Candidate for Heart Failure

GERMANTOWN, Md., Aug. 6, 2020 /PRNewswire/ -- Precigen Triple-Gene, a clinical stage cardiovascular g... See more »
June 22, 2020centralcharts

Preclinical Data for PRGN-3005 UltraCAR-T Demonstrate Superior Expansion and Persistence of UltraCAR-T Compared to Traditional CAR-T

Preclinical Data for PRGN-3005 UltraCAR-T® Demonstrate Superior Expansion and Persistence of UltraCAR... See more »

Precigen Videos

Social Media

Precigen Headquarters

20374 Seneca Meadows Parkway

Germantown, Maryland20876

1-301-556-9900

Driving Directions »

Trending Companies

Precigen Summary

ABOUT

Overview

Precigen is a pharmaceutical company that develops gene and cellular therapies for the treatment of immuno-oncology and autoimmune disorders. Precigen was founded in 1998. Precigen's headquarters is located in Germantown, Maryland, USA 20876. It has r...

CEO

Precigen's President & CEO, Helen Sabzevari, currently has an approval rating of 89%. Precigen's primary competitors are Kite Pharma, Incyte & Poseida Therapeutics.

Frequently Asked Questions about Precigen

  1. When was Precigen founded?

    Precigen was founded in 1998
  2. Who is Precigen's CEO?

    Precigen's CEO is Helen Sabzevari
  3. How much revenue does Precigen generate?

    Precigen generates $97.9M in revenue
  4. How much funding does Precigen have?

    Precigen has historically raised $1B in funding
  5. Where is Precigen's headquarters?

    Precigen's headquarters is in Germantown Maryland, USA
  1. How many employees does Precigen have?

    Precigen has 882 employees
  2. What sector does Precigen operate in?

    Precigen is in Pharmaceuticals
  3. Who are Precigen's competitors?

    Precigen's top competitors are Kite Pharma, Incyte, Poseida Therapeutics
  4. Who has Precigen invested in?

    Precigen's has invested in companies such as Oragenics